The implementation of a cystic fibrosis annual review process in a tertiary paediatric hospital
Raffaela Armiento1, Sarath C Ranganathan1, Joanne Harrison1
1Respiratory Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia.
Insights
Implementing an annual review process for cystic fibrosis (CF) in a children's hospital improved patient care. The study showed increased use of inhaled mucolytic agents, a key treatment for CF.
Area of Science:
- Pediatric Medicine
- Respiratory Medicine
- Clinical Process Improvement
Background:
- Cystic Fibrosis (CF) requires ongoing management and monitoring.
- Annual reviews are crucial for optimizing CF care and outcomes.
- Standardizing the annual review process can enhance treatment adherence and effectiveness.
Purpose of the Study:
- To assess the impact of implementing a structured annual review process for pediatric cystic fibrosis patients.
- To evaluate changes in key clinical outcome measures following the introduction of the new process.
Main Methods:
- A tertiary pediatric hospital implemented a standardized cystic fibrosis annual review protocol.
- Data on patient management and treatment adherence were collected and analyzed pre- and post-implementation.
- Specific focus on the utilization of inhaled mucolytic agents as a primary outcome measure.
Main Results:
- The implementation of the cystic fibrosis annual review process was successfully achieved.
- A significant improvement was observed in the utilization of inhaled mucolytic agents among pediatric CF patients.
- This indicates enhanced adherence to recommended therapies post-implementation.
Conclusions:
- A standardized annual review process is an effective strategy for improving cystic fibrosis care in pediatric settings.
- The observed increase in inhaled mucolytic agent use suggests better management and potentially improved patient outcomes.
- This initiative highlights the value of structured clinical pathways in managing chronic pediatric diseases.
Abstract:
We evaluated the implementation of a cystic fibrosis annual review process in a tertiary paediatric hospital. After implementation, there was demonstrated improvement in an important outcome measure-the use of inhaled mucolytic agents.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Hospitals-II
Nurses that work in...
Hospitals-I
Role of Communication in the Nursing Process II: Planning and Implementation
Tertiary Healthcare System


